• 1
    Henderson A, Ismail AK, Cunningham M et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol 2004; 16: 95104
  • 2
    Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 210631
  • 3
    Institute for Clinical and Economic Review. Management Options for Low-Risk Prostate Cancer: A Report on Comparative Effectiveness and Value. Boston: Institute for Clinical and Economic Review, 2010
  • 4
    Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 2533
  • 5
    D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974
  • 6
    Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491500
  • 7
    Kuban DA, Levy LB, Potters L et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 65: 148793
  • 8
    Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 154957
  • 9
    Vroege JA. The sexual health inventory for men (IIEF-5). Int J Impot Res 1999; 11: 177
  • 10
    Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 31926
  • 11
    Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 893902
  • 12
    Mabjeesh N, Chen J, Beri A, Stenger A, Matzkin H. Sexual function after permanent I125-brachytherapy for prostate cancer. Int J Impot Res 2005; 17: 96101
  • 13
    van Andel G, Bottomley A, Fossa SD et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008; 44: 241824
  • 14
    Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998; 7: 291––300
  • 15
    Downs TM, Sadetsky N, Pasta DJ et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer – data from CaPSURE. J Urol 2003; 170: 18227
  • 16
    Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166: 180410
  • 17
    Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 61423
  • 18
    Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol 2004; 172: 5159
  • 19
    Litwin MS, Gore JL, Kwan L et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007; 109: 223947
  • 20
    Namiki S, Satoh T, Baba S et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology 2006; 68: 12306
  • 21
    Pinkawa M, Asadpour B, Piroth MD et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer – a matched-pair comparison. Radiother Oncol 2009; 91: 22531
  • 22
    Stone NN, Stock RG. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy 2003; 2: 329
  • 23
    Talcott JA, Manola J, Clark JA et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 397986
  • 24
    Tsui G, Gillan C, Pond G, Catton C, Crook J. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy. Cancer J 2005; 11: 12232
  • 25
    Gutman S, Merrick GS, Butler WM et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 2006; 97: 628
  • 26
    Schafer JW, Welzel G, Trojan L et al. Long-term health-related quality-of-life outcomes after permanent prostate brachytherapy. Onkologie 2008; 31: 599603
  • 27
    Lesperance RN, Kjorstadt RJ, Halligan JB, Steele SR. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer. Am J Surg 2008; 195: 61620
  • 28
    Ash D, Bottomley D, Al-Qaisieh B, Carey B, Gould K, Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 2007; 84: 1359
  • 29
    Miller DC, Sanda MG, Dunn RL et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005; 23: 277280
  • 30
    Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 4369
  • 31
    Taira AV, Merrick GS, Galbreath RW et al. Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 63948
  • 32
    Merrick GS, Wallner KE, Galbreath RW et al. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer. Am J Clin Oncol 2008; 31: 53944
  • 33
    Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007; 69: 33842
  • 34
    Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006; 97 (Suppl. 2): 36
  • 35
    Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27: 391622
  • 36
    Keyes M, Miller S, Moravan V et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys 2009; 75: 64955
  • 37
    Nobes JP, Khaksar SJ, Hawkins MA, Cunningham MJ, Langley SE, Laing RW. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. Radiother Oncol 2008; 88: 1216
  • 38
    Merrick GS, Butler WM, Wallner KE et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 54: 105562